Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lung Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm
Lung Neoplasm

Cancer Family

Lung Neoplasm

CI-CAN-00000221Explore in graph →

Non-malignant2,726 active trials51 approved drugs619 evidence items

NCIt: C3200
MeSH: D008175

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11603
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–325 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
· J Clin Oncol · 2011 · PMID 22025157 · validated civic_curation pubmed
Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
· Cancer · 2016 · PMID 27315356 · validated civic_curation pubmed
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
· PLoS One · 2016 · PMID 27032107 · validated civic_curation pubmed
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
· BMC Cancer · 2019 · PMID 31208370 · validated civic_curation pubmed
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
· NPJ Precis Oncol · 2025 · PMID 40069402 · validated civic_curation pubmed
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
· Clin Cancer Res · 2020 · PMID 31548347 · validated civic_curation pubmed
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
· J Thorac Oncol · 2012 · PMID 22895145

Showing 301–325 of 483 publications

← Previous
1
…
12
13
14
…
20
Next →

· validated civic_curation

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

· Mol Cancer Ther · 2013 · PMID 23371856 · validated civic_curation pubmed

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

· Sci Transl Med · 2013 · PMID 24353160 · validated civic_curation pubmed

Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.

· Respir Investig · 2016 · PMID 27566387 · validated civic_curation pubmed

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

· N Engl J Med · 2010 · PMID 20979473 · validated civic_curation pubmed

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

· Sci Transl Med · 2012 · PMID 22277784 · validated civic_curation pubmed

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

· Cancer Res · 2011 · PMID 21791641 · validated civic_curation pubmed

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

· Clin Cancer Res · 2012 · PMID 22235099 · validated civic_curation pubmed

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

· N Engl J Med · 2016 · PMID 26698910 · validated civic_curation pubmed

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

· Ann Oncol · 2016 · PMID 26598547 · validated civic_curation pubmed

Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.

· Lung Cancer · 2015 · PMID 25601188 · validated civic_curation pubmed

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

· Lung Cancer · 2015 · PMID 26559459 · validated civic_curation pubmed

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

· N Engl J Med · 2013 · PMID 23724914 · validated civic_curation pubmed

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

· Clin Cancer Res · 2014 · PMID 25228534 · validated civic_curation pubmed

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

· Cancer Discov · 2016 · PMID 27694386 · validated civic_curation pubmed

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.

· Cancer Biol Ther · 2014 · PMID 24755888 · validated civic_curation pubmed

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

· PLoS Med · 2005 · PMID 15737014 · validated civic_curation pubmed

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

· J Thorac Oncol · 2020 · PMID 31988000 · validated civic_curation pubmed

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

· Cancer Discov · 2016 · PMID 27102076 · validated civic_curation pubmed